Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
NCT00320710
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
416
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Zoledronic acid
DRUG:
Placebo
Sponsor
Novartis Pharmaceuticals